Early Alzheimer's pathology was not consistently linked to depressive symptoms in people without clinical dementia, cross-sectional data suggested. In people with normal cognition, depressive symptoms ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Why: Depression is common in late life, effecting nearly five million of the 31 million Americans aged 65 and older. Both major and minor depression are reported in 13% of community dwelling older ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

Marked variation in the prevalence of depression was found in a multisite sample of community-dwelling older adults in the United States.

Of more than 2,600 US healthcare workers who participated in a nationwide online panel survey from 2022 to 2023, 26% reported ...

Stimulating either of a pair of crucial nerves that carry messages from the brain to several major organs could be an ...